Supporting Better Outcomes in Wound Care
Merakris Therapeutics Wound Care portfolio is based on proprietary advancements in amniotic tissue processing. We work with world-class institutions for a ready supply of product, produced to stringent quality standards.
And the Merakris difference means the highest quality products, fast shipments, technical support and reimbursement guidance.
Dermacyte® Amniotic Wound Care Matrix (Dermacyte Matrix) is a human amniotic membrane allograft with a preserved epithelial basement membrane and compact fibroblast layer.
Dermacyte Matrix provides provides a protective extracellular matrix barrier for use in covering wounds and soft tissue. The product may be used as barrier to protect diabetic ulcers, venous ulcers, pressure ulcers, burn, and other dermal ulcerations that include wounds with exposed vital structures such as tendon, muscle, or bone.
Product SKU Identifier Size (L x W, centimeters)
AM-D10012 MT10012 1 x 2
AM-D10022 MT10022 2 x 2
AM-D10023 MT10023 2 x 3
AM-D10024 MT10024 2 x 4
AM-D10044 MT10044 4 x 4
AM-D10046 MT10046 4 x 6
AM-D10048 MT10048 4 x 8
AM-D10912 MT10912 9 X 12
Dermacyte Matrix is intended for use as a protective covering to provide a barrier to underlying tissue.
Merakris offers a comprehensive Reimbursement Guide for providers using Dermacyte.
To get your copy, complete this form and we'll be in touch shortly.
Reimbursement Guide Request
Dermacyte Matrix is regulated by the U.S. Food and Drug Administration (FDA) as a minimally manipulated human allograft tissue under its Human Cells, Tissues, and Tissue-Based Products (HCT/P) guidelines, subject to Section 361 of the Public Health Service Act and 21 CFR 1270 and 1271.